Our new Editors-in-Chief, Dr. Amy LeBlanc and Prof. David Killick, answer 5 questions on their research backgrounds, career highlights, and their plans for Veterinary Oncology.
To read the Q&A, visit the Springer Nature Cancer Community page.
Dr. Amy LeBlanc, BS, DVM, DipACVIM (Onc), National Cancer Institute, NIH, USA
Dr. Amy LeBlanc is a board-certified veterinary oncologist, Senior Scientist and Director of the CCR Comparative Oncology Program at the National Cancer Institute, NIH. In this position, she directly oversees and manages the operations of the Comparative Oncology Trials Consortium (COTC), which designs and executes clinical trials of new cancer therapies in tumor-bearing pet dogs. Dr. LeBlanc is a graduate of Michigan State University, holding both BS and DVM degrees.
Prof. David Killick, BVetMed PgDip-AP, PhD, CertSAM DipECVIM-CA (Onc), FHEA, FRCVS, RCVS Specialist, and EBVS® European Specialist in Veterinary Oncology (Small Animals), University of Liverpool, UK
David is Professor of Small Animal Oncology at the University of Liverpool, UK and current Chair of the ECVIM Oncology Specialty Group. He is interested in all aspects of clinical oncology especially treatment of canine melanoma and lymphoma in the cat and dog. David’s current research interests include tumour registries, medication safety and cancer immunology. He received his PhD and BVetMed from the Royal Veterinary College, University of London.